Imperial College London
Mrs Hanna Box, MPH - Global Health

Mrs Hanna Box, MPH - Global Health

Faculty of Medicine, School of Public Health

Operations Manager - Clinical Research
 
 
 
//

Contact

 

h.box

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fidler:2020:10.1016/S0140-6736(19)32990-3,
author = {Fidler, S and Sthr, W and Pace, M and Dorrell, L and Lever, A and Pett, S and Kinloch-de, Loes S and Fox, J and Clarke, A and Nelson, M and Thornhill, J and Khan, M and Fun, A and Bandara, M and Kelly, D and Jakub, K and Hanke, T and Yang, H and Bennett, R and Johnson, M and Howell, B and Richard, B and Wu, G and Kaye, S and Wills, M and Babiker, A and Frater, J},
doi = {10.1016/S0140-6736(19)32990-3},
journal = {The Lancet},
pages = {888--898},
title = {A randomized comparison of antiretroviral therapy alone versus antiretroviral therapy with a 'kick-and-kill' approach, on measures of the HIV reservoir amongst participants with recent HIV infection: the RIVER trial},
url = {http://dx.doi.org/10.1016/S0140-6736(19)32990-3},
volume = {395},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells. Approaches that force HIV transcription from these cells, making them susceptible to killing - termed ‘kick and kill’ - have been explored as a strategy towards an HIV cure. RIVER is the first randomized trial to determine the impact of ART alone versus ART plus ‘kick-and-kill’ on markers of the HIV reservoir.Methods: RIVER (Trial registration: NCT02336074) was an open-label, multicenter, 1:1 randomized controlled trial of ART-only (control) versus ART plus the histone deacetylase inhibitor vorinostat (the ‘kick’) and replication-deficient viral vector vaccines encoding conserved HIV sequences ChAdV63.HIVconsv-prime, MVA.HIVconsv-boost T-cell vaccination (the ‘kill’) (ART+V+V; intervention) in HIV-positive adults treated in recent HIV-infection. The primary endpoint was total HIV DNA in peripheral blood CD4+ T-cells at weeks 16 and 18 post-randomization. Secondary endpoints included safety, alternative measures of the HIV reservoir including quantitative viral outgrowth, HIV-specific T-cell frequencies, and CD8+ T-cell mediated viral inhibition.Findings: Between December 2015 and November 2017, 60 HIV-positive male participants were randomized (computer-based and stratified by time since diagnosis; 30 participants in each trial arm) and completed the study interventions, with no loss-to-follow-up. There were no intervention-related serious adverse events. Mean total HIV DNA at weeks 16 and 18 was 3.02 log10 copies HIV DNA/106 CD4+ T-cells in the control and 3.06 log10 copies HIV DNA/106 CD4+ T-cells in the intervention arm, with no statistically significant difference (mean difference of 0.04 (95%CI -0.03, 0.11) log10 total HIV DNA copies/106 CD4+ T-cells (p=0.26)). Interpretation: This ‘kick-and-kill’ approach conferred no significant benefit compared to ART alone on measures of
AU  - Fidler,S
AU  - Sthr,W
AU  - Pace,M
AU  - Dorrell,L
AU  - Lever,A
AU  - Pett,S
AU  - Kinloch-de,Loes S
AU  - Fox,J
AU  - Clarke,A
AU  - Nelson,M
AU  - Thornhill,J
AU  - Khan,M
AU  - Fun,A
AU  - Bandara,M
AU  - Kelly,D
AU  - Jakub,K
AU  - Hanke,T
AU  - Yang,H
AU  - Bennett,R
AU  - Johnson,M
AU  - Howell,B
AU  - Richard,B
AU  - Wu,G
AU  - Kaye,S
AU  - Wills,M
AU  - Babiker,A
AU  - Frater,J
DO  - 10.1016/S0140-6736(19)32990-3
EP  - 898
PY  - 2020///
SN  - 0140-6736
SP  - 888
TI  - A randomized comparison of antiretroviral therapy alone versus antiretroviral therapy with a 'kick-and-kill' approach, on measures of the HIV reservoir amongst participants with recent HIV infection: the RIVER trial
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(19)32990-3
UR  - https://www.sciencedirect.com/science/article/pii/S0140673619329903?via%3Dihub
UR  - http://hdl.handle.net/10044/1/75261
VL  - 395
ER  -
Download